With careful dose increases, close medical follow-up, and clear guidance on nutrition and hydration, most patients find that these symptoms ease as their body adjusts
If there are no gastrointestinal symptoms, but GLP-1 receptor agonists are not held, proceed with full stomach precautions, or consider evaluating gastric volume by ultrasound
Vestlund and Jerlhag, 2020b), the possibility that patients with other addictions might benefit from GLP-1R therapies should be considered
Finally, IGF-1 appears to promote the differentiation of myoblasts
J.FrancauxM.CuisinierC.SturboisX.De WitteP
Many patients beginning tirzepatide therapy start at the 5mg injection dose to assess tolerance and response